Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.EraGen Biosciences, a developer of molecular reagent products, has received Health Canada approval to market five molecular testing products as in-vitro diagnostics in the Canadian market.
Subscribe to our email newsletter
The approved EraGen molecular diagnostic tests are performed on the company’s MultiCode-RTx real-time polymerase chain reaction (PCR) system. The MultiCode-RTx system reportedly simplifies and enhances traditional real-time PCR through the use of EraGen’s proprietary synthetic iC and iG base pair.
The system provides clinicians and laboratories with more laboratory workflow, reduced time to test result, and the flexibility to run EraGen tests on virtually any quantitative PCR instrument.
The EraGen molecular diagnostic tests approved by Health Canada are bordetella pertussis and parapertussis, enterovirus, influenza types A and B, herpes simplex virus 1 and 2, and cytomegalovirus.
Irene Hrusovsky, president and CEO of EraGen, said: “Health Canada’s approval of five EraGen molecular diagnostics is another significant step forward in the execution of the company’s product commercialization strategy. We are committed to expanding our molecular diagnostics business into multiple rapidly-growing markets outside of the US.”